<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82183">
  <stage>Registered</stage>
  <submitdate>14/11/2007</submitdate>
  <approvaldate>21/11/2007</approvaldate>
  <actrnumber>ACTRN12607000599471</actrnumber>
  <trial_identification>
    <studytitle>Study in healthy Australian adult subjects comparing the standard commercial flu vaccine with an enhanced flu vaccine containing a natural plant-derived immune enhancer</studytitle>
    <scientifictitle>A randomised, controlled Phase 1/2 study in healthy adults of a seasonal influenza vaccine containing an inulin-based adjuvant to evaluate safety and immunogenicity</scientifictitle>
    <utrn />
    <trialacronym>FLU001</trialacronym>
    <secondaryid>FLU001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Seasonal influenza prevention</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Public Health</conditioncode1>
      <conditioncode2>Epidemiology</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Comparison of intramuscular administration of reduced dose seasonal trivalent inactivated influenza vaccine (15micrograms) containing Advax adjuvant (20mg) versus standard dose intramuscular seasonal trivalent inactivated influenza vaccine (45 micrograms)</interventions>
    <comparator>Commercial trivalent inactivated seasonal influenza vaccine (45 micrograms) administered by intramuscular injection into deltoid muscle</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of adverse events</outcome>
      <timepoint>21 days from immunisation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Seroconversion and seroprotection against influenza measured according to Therapeutic Goods Administration (TGA) criteria as contained in Harmonisation of Requirements for Influenza Vaccines, Directive 75/318/EEC as amended</outcome>
      <timepoint>21 days post immunisation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Kinetics of immunological responses to influenza vaccine (antibody and T cell responses)</outcome>
      <timepoint>T cell responses to influenza haemaggutinin as measured 21 days post-immunisation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria> Non-pregnant
 If child bearing age, using contraception (barrier method, intrauterine device (IUD) or oral contraception)
 Able to provide written informed consent 
 Willing and able to comply with the protocol for the duration of the study.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria> Known immunodeficiency  (including human immunodeficiency virus (HIV)
  diabetes mellitus
 History of vaccine or egg allergy
 Women of childbearing potential unless using a reliable and appropriate contraceptive method, specifically oral contraceptive pill, intrauterine device (IUD) or mechanical barrier device. 
 Pregnant or lactating women. 
 Concurrent immunosuppressive therapy, including corticosteroids (with the exception of topically applied/inhaled steroids).
 Participation in another clinical trial with an investigational agent within 30 days preceding initiation of treatment.
 History of intravenous drug abuse or alcohol abuse</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Blinded envelopes</concealment>
    <sequence>Random number generator (www.randomization.com)</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>1/07/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>150</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>5042</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Vaxine Pty Ltd</primarysponsorname>
    <primarysponsoraddress>Flinders Medical Centre
Adelaide SA 5042</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Vaxine Pty Ltd</fundingname>
      <fundingaddress>Flinders Medical Centre
Adelaide SA 5042</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A major challenge in influenza vaccines is to find a way to deliver considerably lower doses of influenza vaccine while still being able to elicit a protective immune response. This is because the number of doses of seasonal influenza vaccine able to be generated is limited by production capacity and cost.Extensive animal data indicates addition of a natural plant sugar called Advax  results in enhanced immunity and/or reduced antigen requirements compared to current unadjuvanted human influenza vaccines. This study will test the safety and effectiveness of a low dose flu vaccine containing Advax to the standard full dose commercial flu vaccine.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Flinders Clinical Research Ethics Committee</ethicname>
      <ethicaddress>Flinders Medical Centre
Adelaide SA 5042</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Nikolai Petrovsky</name>
      <address>Flinders Medical Centre
Adelaide SA 5042</address>
      <phone>+61 8 82044572</phone>
      <fax>+61 8 82045987</fax>
      <email>nikolai.petrovsky@flinders.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Nikolai Petrovsky</name>
      <address>Flinders Medical Centre
Adelaide SA 5042</address>
      <phone>+61 8 82044572</phone>
      <fax>+61 8 82045987</fax>
      <email>nikolai.petrovsky@flinders.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Nikolai Petrovsky</name>
      <address>Flinders Medical Centre
Adelaide SA 5042</address>
      <phone>+61 8 82044572</phone>
      <fax>+61 8 82045987</fax>
      <email>nikolai.petrovsky@flinders.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>